Pharmacokinetics and pharmacodynamics of nilotinib in gastrointestinal stromal tumors

Seminars in Oncology

Volumn 38, Issue 1 SUPPL., 2011, Pages

  Trent, Jonathan ^a   Molimard, Mathieu ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 INHIBITOR; ESOMEPRAZOLE; IMATINIB; NILOTINIB; SUNITINIB; WARFARIN;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; ARTICLE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG OXIDATION; FATIGUE; FOOD DRUG INTERACTION; GASTROINTESTINAL STROMAL TUMOR; GRAPEFRUIT JUICE; HEART ARRHYTHMIA; HUMAN; HYPERBILIRUBINEMIA; HYPOPHOSPHATEMIA; LIPID DIET; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RASH; SINGLE DRUG DOSE;

CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; TISSUE DISTRIBUTION;

EID: 79952770929     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.01.014     Document Type: Article

References (25)

1. O.S. Din, and P.J. Woll Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate Ther Clin Risk Manag 4 2008 149 162 (Pubitemid 351460941)
2. NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma www.nccn.org.2010 Accessed August 27, 2010
3. P.G. Casali, and J.Y. Blay Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 Suppl 5 2010 v98 v102
4. Y. Jiang, L. Ming, and A.J. Montero Optimizing imatinib mesylate treatment in gastrointestinal stromal tumors Gastrointest Cancer Res 2 2008 245 250
5. A.Y. Khakoo, C.M. Kassiotis, and N. Tannir Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor Cancer 112 2008 2500 2508
6. S. Dirnhofer, and S. Leyvraz Current standards and progress in understanding and treatment of GIST Swiss Med Wkly 139 2009 90 102
7. G.D. Demetri, R.S. Benjamin, and C.D. Blanke NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)update of the NCCN clinical practice guidelines J Natl Compr Canc Netw 5 Suppl 2 2007 S1 S29
8. A.A. Izzo, and E. Ernst Interactions between herbal medicines and prescribed drugs: an updated systematic review Drugs 69 2009 1777 1798
9. Novartis Pharmaceuticals Corporation Tasigna (Nilotinib) prescribing information http://www.us.tasigna.com/patient/full-prescribing-information.jsp. 2010 Accessed August 4, 2010
10. C. Fava, H. Kantarjian, J. Cortes, and E. Jabbour Development and targeted use of nilotinib in chronic myeloid leukemia Drug Des Devel Ther 2 2009 233 243
11. M. Kagan, P. Tran, and V. Fischer Safety, pharmacokinetics (PK), metabolism, and mass balance of [14C]-AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl tyrosine kinase, in healthy subjects ASH Annual Meeting Abstracts 106 2005 4887
12. H. Kantarjian, F. Giles, and L. Wunderle Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL N Engl J Med 354 2006 2542 2551 (Pubitemid 43882350)
13. G.D. Demetri, P.G. Casali, and J.Y. Blay A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors Clin Cancer Res 15 2009 5910 5916
14. O. Yin, N.J. Gallagher, and D. Fischer Effect of nilotinib on the pharmacokinetics and pharmacodynamics of warfarin [abstract 7063] J Clin Oncol 27 2009 15s
15. J. Kiani, and S.Z. Imam Medicinal importance of grapefruit juice and its interaction with various drugs Nutr J 6 2007 33
16. O.Q. Yin, N. Gallagher, and A. Li Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants J Clin Pharmacol 50 2010 188 194
17. European Medicines Agency Tasignaprocedural steps taken and scientific information after the authorisation http://www.emea.europa.eu/humandocs/PDFs/ EPAR/tasigna/H-798-en8.pdf.2009 Accessed January 1, 2010
18. N.J. Gallagher, D. Fischer, and E. Demirhan Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib [abstract 7053] J Clin Oncol 27 2009 15s
19. C. Tanaka, O.Q. Yin, and V. Sethuraman Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib Clin Pharmacol Ther 87 2010 197 203
20. M. Montemurro, P. Schoffski, and P. Reichardt Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib Eur J Cancer 45 2009 2293 2297
21. M.W. Deininger Nilotinib Clin Cancer Res 14 2008 4027 4031
22. Gleevec/Glivec Prescribing information http://www.gleevec.com/utils/ pdfxfer/prepdf. jsp Accessed September 8, 2010
23. C.E. de Kogel, and J.H. Schellens Imatinib Oncologist 12 2007 1390 1394
24. H.K. Gan, B. Seruga, and J.J. Knox Sunitinib in solid tumors Expert Opin Invest Drugs 18 2009 821 834
25. Pfizer Sutent prescribing information http://www.pfizer.com/files/ products/uspi-sutent pdf Accessed September 8, 2010